Visual function disorder improving agents

The agent of any of claims. 1 to 3, wherein the compound having a Rho kinase inhibitory activity is an amide compound of the following formula (I)

• 9
• wherein
• Ra is a group of the formula
• 10
• in the formulas (a) and (b),
• R is hydrogen, alkyl, or cycloalkyl, cycloalkylalkyl, phenyl or aralkyl, which optionally has a substituent on the ring, or a group of the formula
• 11
• wherein R6 is hydrogen, alkyl or formula:—NR8R9 wherein R8 and R9 are the same or different and each is hydrogen, alkyl, aralkyl or phenyl, R7 is hydrogen, alkyl, aralkyl, phenyl, nitro or cyano, or R6 and R7 in combination show a group forming a heterocycle optionally further having, in the ring, oxygen atom, sulfur atom or optionally substituted nitrogen atom,
• R1 is hydrogen, alkyl, or cycloalkyl, cycloalkylalkyl, phenyl or aralkyl, which optionally has a substituent on the ring, or
• R and R1 in combination form, together with the adjacent nitrogen atom, a group forming a heterocycle optionally further having, in the ring, oxygen atom, sulfur atom or optionally substituted nitrogen atom,
• R2 is hydrogen or alkyl,
• R3 and R4 are the same or different and each is hydrogen, alkyl, aralkyl, halogen, nitro, amino, alkylamino, acylamino, hydroxy, alkoxy, aralkyloxy, cyano, acyl, mercapto, alkylthio, aralkylthio, carboxy, alkoxycarbonyl, carbamoyl, mono- or dialkylcarbamoyl or azide, and
• A is a group of the formula
• 12
• wherein R10 and R11 are the same or different and each is hydrogen, alkyl, haloalkyl, aralkyl, hydroxyalkyl, carboxy or alkoxycarbonyl, or R10 and R11 show a group which forms cycloalkyl in combination and l, m and n are each 0 or an integer of 1-3,
• in the formula (c),
• L is hydrogen, alkyl, aminoalkyl, mono- or dialkylaminoalkyl, tetrahydrofurfuryl, carbamoylalkyl., phthalimidoalkyl, amidino or a group of the formula
• 13
• wherein B is hydrogen, alkyl, alkoxy, aralkyl, aralkyloxy, aminoalkyl, hydroxyalkyl, alkanoyloxyalkyl, alkoxycarbonylalkyl, α-aminobenzyl, furyl, pyridyl, phenyl, phenylamino, styryl or imidazopyridyl,
• Q1 is hydrogen, halogen, hydroxy, aralkyloxy or thienylmethyl,
• W is alkylene,
• Q2 is hydrogen, halogen, hydroxy or aralkyloxy,
• X is alkylene,
• Q3 is hydrogen, halogen, hydroxy, alkoxy, nitro, amino, 2,3-dihydrofuryl or 5-methyl-3-oxo-2,3,4,5-tetrahydropyridazin-6-yl;
• and
• Y is a single bond, alkylene or alkenylene, and
• in the formula (c),
• a bond denoted by a broken line and a solid line is a single bond or a double bond;
• R5 is hydrogen, hydroxy, alkoxy, alkoxycarbonyloxy, alkanoyloxy or aralkyloxycarbonyloxy;
• Rb is a hydrogen, an alkyl, an aralkyl, an aminoalkyl or a mono- or dialkylaminoalkyl;
• and
• Rc is an optionally substituted heterocycle containing nitrogen,
• an isomer thereof and/or a pharmaceutically acceptable acid addition salt thereof, or a prodrug thereof.